Author Claim Review

 Quick Explanation Copied

 Long Explanation

Citation Metrics and Output Trajectory

The primary OpenAlex cluster for Kiavash Hushmandi (A5041093222) reports 315 works, 22,270 citations, and an h-index of 69; the Semantic Scholar-style author profile lists h-index 64 with 14,333 citations across 322 papers — a discrepancy reflecting database fragmentation, since several secondary OpenAlex clusters (h-index 0–4) split his record. Output accelerated sharply from 2020 onward, peaking at 68 works in 2025, with citations per year rising from 731 (2021) to ~7,817 (2025). This trajectory is dominated by two pillars: (1) Global Burden of Disease (GBD) consortium papers in The Lancet, including the flagship 371-disease burden analysis with 5,091 citations GBD 2021 flagship Lancet paper (5,091 citations) and the GBD 2023 risk-factor analysis GBD 2021 risk-factor Lancet paper (2,871 citations); and (2) narrative/systematic reviews in cancer molecular biology, notably a 564-citation exosome review in Journal of Hematology & Oncology Exosome cancer review, J Hematol Oncol (564 citations) and EMT/cisplatin-resistance work EMT-cisplatin resistance review (249 citations).

Scientific Strengths

His highest-independence contributions appear in regional epidemiology (Iran cancer incidence trends, TB surveillance, COVID-19 clinical cohorts from Kerman/Jiroft) and translational reviews on non-coding RNAs, autophagy, and drug resistance. A high-impact recent review in Molecular Cancer (279 citations) on glioblastoma signaling demonstrates capacity for authoritative synthesis GBM review in Molecular Cancer (279 citations). The breadth across oncology, diabetes, nanomedicine, and public health indicates strong collaborative networks and synthesis skills.

Critical Red Flags and Blindspots

Several serious concerns temper the bibliometric picture. First, multiple retractions: the supplied record contains at least five retraction notices, including the 403-citation AMPK/diabetes review Retraction of AMPK diabetes review, plus retractions concerning paclitaxel/docetaxel resistance (twice), NF-kB/diabetic complications (Heliyon), and gene regulation by antisense transcription. Retraction of >400-citation work is a material integrity signal. Second, extreme volume (68 papers in 2025; >300 total in ~8 years) with predominantly review articles and consortium middle-authorship suggests assembly-line review production rather than deep original research; most supplied papers are reviews, systematic reviews, or meta-analyses, with comparatively few primary experimental studies. Third, citation inflation from GBD consortium authorship means the h-index overstates individual scientific contribution. Fourth, affiliation data are inconsistent (University of Tehran vs Shiraz/Kerman entries), and the primary OpenAlex cluster lists no primary institution. GBD methodology itself relies on model-based estimation with known limitations in low-data regions, which the consortium acknowledges.

Verdict

Hushmandi is a highly productive, well-networked review author and consortium contributor with genuinely useful synthesis output and strong regional epidemiology work, but his metrics are inflated by large-group authorship and his record carries an unusual density of retractions that warrant caution when citing his review literature. Confidence: moderate — based solely on the supplied metadata; full-text quality audits and retraction reasons are not available here.

 BGPT Author Review

Scientific Quality

High bibliometric output (h-index 64–69, ~22k citations) but heavily inflated by GBD consortium middle-authorship and review-mill productivity. Multiple retractions of highly cited reviews (including one with 403 citations) are a significant integrity red flag. Limited evidence of deep primary experimental research; most output is narrative reviews and systematic reviews with large collaboration groups.

Communication Quality

Reviews are structurally comprehensive with extensive references, and publication venues are generally appropriate. However, extremely high output volume raises questions about depth per manuscript, and retraction/corrigendum corrections suggest lapses in manuscript care.

Author Novelty

Most work is synthesis of established molecular pathways (NF-kB, AMPK, EMT, STAT3, non-coding RNAs) and consortium epidemiology. Little evidence of conceptually new hypotheses, methods, or original discoveries.

Scientific Rigor

Systematic reviews and GBD analyses follow established protocols, but the pattern of multiple retractions in mid-tier pharmacology journals, extreme publication velocity, and reliance on narrative synthesis rather than hypothesis-driven experimentation indicate rigor concerns. Primary clinical studies are mostly small, single-center, retrospective designs.